Title

Stereotaxic-assisted gene therapy in Alzheimer’s and Parkinson’s diseases: therapeutic potentials and clinical frontiers

Document Type

Article

Abstract

Introduction: Alzheimer’s disease (AD) and Parkinson’s disease (PD) are neurodegenerative disorders causing cognitive deficits and motor difficulties in the elderly. Conventional treatments are mainly symptomatic with little ability to halt disease progression. Gene therapies to correct or silence genetic mutations predisposing to AD or PD are currently being developed in preclinical studies and clinical trials, relying mostly on systemic delivery, which reduces their effectiveness. Imaging-guided stereotaxic procedures are used to locally deliver therapeutic cargos to well-defined brain sites, hence raising the question whether stereotaxic-assisted gene therapy has therapeutic potentials. Areas covered: The authors summarize the studies that investigated the use of gene therapy in PD and AD in animal and clinical studies over the past five years, with a special emphasis on the combinatorial potential with stereotaxic delivery. The advantages, limitations and futuristic challenges of this technique are discussed. Expert opinion: Robotic stereotaxis combined with intraoperative imaging has revolutionized brain surgeries. While gene therapies are bringing huge innovations to the medical field and new hope to AD and PD patients and medical professionals, the efficient and targeted delivery of such therapies is a bottleneck. We propose that careful application of stereotaxic delivery of gene therapies can improve PD and AD management. (Figure presented.).

Publication Date

1-1-2022

Faculty

Faculty of Pharmacy

Subject Area

Life Sciences, Neuroscience, Health Sciences, General Medicine

Indexed in Scopus

yes

DOI

https://doi.org/10.1080/14737175.2022.2056446

Volume

22

Keywords

CRISPR, nanocarriers, Neurodegeneration, siRNA, stereotaxis

ISSN

14737175

eISSN

17448360

Share

COinS